Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 55/100

Failure Rate

20.0%

2 terminated/withdrawn out of 10 trials

Success Rate

75.0%

-11.5% vs industry average

Late-Stage Pipeline

60%

6 trials in Phase 3/4

Results Transparency

17%

1 of 6 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 3

6(60.0%)

Phase 2

3(30.0%)

Phase 1

1(10.0%)

10Total

Phase 3(6)

Phase 2(3)

Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (10)

Showing 10 of 10 trials

NCT02947685Phase 3Active Not Recruiting

Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer

Role: collaborator

NCT01822314Phase 3Completed

Neoadjuvant Chemotherapy With Nab-paclitaxel in Women With HER2-negative High-risk Breast Cancer

Role: lead

NCT03595592Phase 3Active Not Recruiting

Neoadjuvant Treatment of HER2 Positive Early High-risk and Locally Advanced Breast Cancer

Role: lead

NCT02620280Phase 3Completed

Neoadjuvant Therapy in TRIPle Negative Breast Cancer With antiPDL1

Role: lead

NCT00992030Phase 3Terminated

R-ABVD vs ABVD-RT in Early Stage Hodgkin's Lymphoma

Role: lead

NCT02530424Phase 2Completed

"Neo-Adjuvant Treatment With Palbociclib: Effect on Ki67 and Apoptosis Before, During and After Treatment "

Role: lead

NCT02439489Phase 1Completed

Study of the Combination of BKM120 and Cisplatin or Carboplatin in Patients With Advanced Solid Tumors

Role: lead

NCT01851200Phase 2Completed

Brentuximab Vedotin (SGN-35) as Salvage Treatment for CD30-positive Germ Cell Tumors

Role: lead

NCT01251107Phase 3Completed

Study Comparing ABVD vs BEACOPP in Advanced Hodgkin's Lymphoma

Role: lead

NCT01477060Phase 2Terminated

Modulation of Response to Hormonal Therapy With Lapatinib and/or Metformin in Patients With Metastatic Breast Cancer

Role: lead

All 10 trials loaded